BDR Pharma to launch 80mg of Enzalutamide for treatment of Prostate Cancer in India Kumar Jeetendra | September 21, 2020 Mumbai 21st September 2020: BDR Pharmaceutical today announces the launch of 80mg advanced version of its Enzalutamide drug. BDR Pharma had earlier received approval from the Drugs Controller General of India (DCGI) to manufacture 40mg Enzalutamide in 2017 to treat men with metastatic castration-resistant prostate cancer (mCRPC) under the brand name BDENZA. The 80 mg …
